Building great science into great biotech companies

Germany has exceptional science.

Turning that science into a successful biotech company requires something different.

It requires early choices about what the company should become, which science should be translated into medicines, where to focus limited capital, what evidence will change value, and which capabilities need to be built, and when.

These decisions are often being made while an academic founding team is simultaneously learning how to build a company [BioRN; EY Report 2026].

We help bridge that gap.

We work alongside life science investors and scientific founders to turn promising academic science into focused, investable biotech companies with a clear path to value creation.

We are not traditional consultants. We are experienced biotech and pharmaceutical R&D leaders who have built teams, therapeutic pipelines, discovery organisations and companies from the inside.

Between us, we bring deep experience across disease biology, human genetics and multi-omics, target discovery and validation, translational science, drug discovery and clinical development, together with company creation, portfolio strategy, organisational build, partnering and leadership.

Our starting point is always the same:

What would need to be true for this science to become a successful company?

From there, we work backwards.

We help determine where the strongest therapeutic opportunities lie, what should and should not enter the pipeline, which experiments genuinely reduce risk, what the critical value inflection points are, and how capital should be deployed to reach them.

We then help build the organisation around that strategy.